Millendo Therapeutics

$1.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+8.67%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell MLND and other stocks, options, and ETFs commission-free!

About MLND

Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. Its product pipeline includes Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe for classic congenital adrenal hyperplasia; and Neurokinin 3 receptor for vasomotor symptoms. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. The listed name for MLND is Millendo Therapeutics, Inc. Common Stock.

CEO
Julia C. Owens
Employees
38
Headquarters
Ann Arbor, Michigan
Founded
2012
Market Cap
35.72M
Price-Earnings Ratio
Dividend Yield
Average Volume
324.75K
High Today
$1.88
Low Today
$1.73
Open Price
$1.73
Volume
563.64K
52 Week High
$9.88
52 Week Low
$1.26

Collections

MLND Earnings

-$0.87
-$0.58
-$0.29
-$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, Pre-Market

You May Also Like